IN2015DN00598A - - Google Patents

Download PDF

Info

Publication number
IN2015DN00598A
IN2015DN00598A IN598DEN2015A IN2015DN00598A IN 2015DN00598 A IN2015DN00598 A IN 2015DN00598A IN 598DEN2015 A IN598DEN2015 A IN 598DEN2015A IN 2015DN00598 A IN2015DN00598 A IN 2015DN00598A
Authority
IN
India
Prior art keywords
formula
compound
pharmaceutically acceptable
acceptable salt
embodiment provides
Prior art date
Application number
Inventor
Roger D Tung
Adam J Morgan
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of IN2015DN00598A publication Critical patent/IN2015DN00598A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

The present invention in one embodiment provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof wherein the variables shown in Formula (I) are as defined in the specification.
IN598DEN2015 2012-07-30 2013-07-30 IN2015DN00598A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261677307P 2012-07-30 2012-07-30
PCT/US2013/052721 WO2014022390A1 (en) 2012-07-30 2013-07-30 Deuterated ibrutinib

Publications (1)

Publication Number Publication Date
IN2015DN00598A true IN2015DN00598A (en) 2015-06-26

Family

ID=48917743

Family Applications (1)

Application Number Title Priority Date Filing Date
IN598DEN2015 IN2015DN00598A (en) 2012-07-30 2013-07-30

Country Status (13)

Country Link
US (2) US9422295B2 (en)
EP (1) EP2882751B1 (en)
JP (1) JP6261580B2 (en)
KR (1) KR20150038486A (en)
CN (1) CN104507946A (en)
AU (1) AU2013296627C9 (en)
BR (1) BR112015001839A2 (en)
CA (1) CA2879400A1 (en)
EA (1) EA201590296A1 (en)
ES (1) ES2682043T3 (en)
IN (1) IN2015DN00598A (en)
MX (1) MX2015001246A (en)
WO (1) WO2014022390A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015001246A (en) 2012-07-30 2015-04-10 Concert Pharmaceuticals Inc Deuterated ibrutinib.
CN105017256A (en) * 2014-04-29 2015-11-04 浙江导明医药科技有限公司 Polyfluorinated compound Bruton tyrosine kinase inhibitor
CN103965201A (en) * 2014-04-30 2014-08-06 淮海工学院 Method for synthesizing intermediate 4-amino-3-(4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidine of Ibrutinib
CN104945404B (en) * 2014-06-25 2018-09-14 广东东阳光药业有限公司 A kind of preparation method of N- propenecarbonyls piperidine derivative
MA41350A (en) * 2015-01-14 2017-11-21 Janssen Pharmaceutica Nv SUMMARY OF A BRUTON TYROSINE KINASE INHIBITOR
WO2016127915A1 (en) * 2015-02-12 2016-08-18 上海度德医药科技有限公司 Method for preparing ibrutinib
WO2016132383A1 (en) * 2015-02-18 2016-08-25 Mylan Laboratories Limited Process for the preparation of ibrutinib
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
CN106146508A (en) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 The drug combination optimized and treatment cancer and the purposes of autoimmune disease thereof
WO2016151438A1 (en) * 2015-03-20 2016-09-29 Sun Pharmaceutical Industries Limited A process for the preparation of ibrutinib
BR112018072339A2 (en) * 2016-05-04 2019-02-19 Concert Pharmaceuticals, Inc. treatment of hair loss disorders with deuterated jak inhibitors
JP7118347B2 (en) * 2017-04-04 2022-08-16 コンビフォス カタリスツ インコーポレイテッド Deuterated (S) 2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
TW201922256A (en) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 Methods for treating lymphoid malignancies
CN109988175A (en) * 2019-04-28 2019-07-09 梯尔希（南京）药物研发有限公司 A kind of preparation method for replacing Buddhist nun-d5 according to Shandong
CN112876484B (en) * 2020-08-31 2022-06-28 绍兴舜邦医药科技有限公司 Preparation method of deuterated ibrutinib
CN112125913A (en) * 2020-10-29 2020-12-25 瑞阳制药股份有限公司 Synthesis method of high-purity ibrutinib
CN115611810A (en) * 2021-07-16 2023-01-17 深圳市塔吉瑞生物医药有限公司 Substituted pyrazole compounds, compositions containing the same and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040068613A (en) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 Deuterated compound and composition for treating hypertension
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
PT1104760E (en) 1999-12-03 2003-06-30 Pfizer Prod Inc SULFAMOYL-HETEROARILPIRAZOLE COMPOUNDS AS ANALGESIC AND ANTI-INFLAMMATORY AGENTS
DE10155018A1 (en) 2001-11-07 2003-07-10 Berolina Drug Dev Ab Svedala Deuterated pyrazolopyrimidinones and medicinal products containing these compounds
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
JP2006219373A (en) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pyridinylpyrazolopyrimidinone derivative having pde 7 inhibition
CA2624179A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic Compounds
JP2010502702A (en) 2006-09-05 2010-01-28 シェーリング コーポレイション Pharmaceutical composition for use in lipid management and therapeutic treatment of atherosclerosis and fatty liver
EP2081435B1 (en) 2006-09-22 2016-05-04 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US9212285B2 (en) 2012-02-08 2015-12-15 Council Of Scientific & Industrial Research Electronically conducting carbon and carbon-based material by pyrolysis of dead leaves and other similar natural waste
MX2015001246A (en) 2012-07-30 2015-04-10 Concert Pharmaceuticals Inc Deuterated ibrutinib.

Also Published As

Publication number Publication date
EA201590296A1 (en) 2015-07-30
AU2013296627C1 (en) 2016-12-15
MX2015001246A (en) 2015-04-10
US9777009B2 (en) 2017-10-03
EP2882751A1 (en) 2015-06-17
AU2013296627A1 (en) 2015-02-05
ES2682043T3 (en) 2018-09-18
JP6261580B2 (en) 2018-01-17
WO2014022390A1 (en) 2014-02-06
KR20150038486A (en) 2015-04-08
CA2879400A1 (en) 2014-02-06
AU2013296627B2 (en) 2016-07-14
US20170015670A1 (en) 2017-01-19
JP2015528020A (en) 2015-09-24
US9422295B2 (en) 2016-08-23
AU2013296627C9 (en) 2018-03-22
US20150210699A1 (en) 2015-07-30
BR112015001839A2 (en) 2017-07-04
EP2882751B1 (en) 2018-06-27
CN104507946A (en) 2015-04-08

Similar Documents

Publication Publication Date Title
IN2015DN00598A (en)
MX361499B (en) Deuterated baricitinib.
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
PH12014501653A1 (en) Metalloenzyme inhibitor compounds
IN2015DN00960A (en)
EA201591634A1 (en) DIHYDROPYRIDOPYRIMIDINE COMPOUNDS
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
CR20140468A (en) DIACILGLICEROL ACILTRANSFERASA 2 INHIBITORS
CR20140306A (en) FLUORMETIL -5,6-DIHIDRO-4H- [1,3] OXAZINES
MX2015002487A (en) Process for the preparation of teneligliptin.
JO3318B1 (en) Bace inhibitors
IN2014DN07996A (en)
MX2015008829A (en) Deuterated momelotinib.
CR20140495A (en) 5-AMINO [1,4] THIAZINES AS INHIBITORS OF BACE1
MX2015016332A (en) Pyrrolotriazines as alk inhibitors.
IN2014DN10669A (en)
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
AU2013347232A8 (en) 3-Aminocyclopentane carboxamide derivatives
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
MX2015012610A (en) Deuterated pacritinib.
EA201690593A1 (en) NEW UREA COMPOUNDS
IN2013CH05395A (en)
MX2015001134A (en) Therapeutic compounds.
UA72478U (en) Use of polentar as frigoprotector